publication date: Oct. 27, 2017
Issue 40 - Oct. 27, 2017
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
  • Redefining “normal”: IU’s Komen Tissue Bank shows how race and abnormalities correlate with development of disease

    When two women—a patient advocate and a scientist—embarked on a mission to collect “normal” breast tissue for comparative purposes, colleagues in oncology dismissed their idea as wild.

    In the early 2000s, Connie Rufenbarger, a breast cancer patient advocate, and Anna Maria Storniolo, a professor of clinical medicine at the Indiana University School of Medicine and a member of the Vera Bradley Foundation for Breast Cancer Research Laboratories, were attending a meeting in Indianapolis when they realized that oncologists had no source of “true normal” breast tissue to use as control in studies.

  • Conversation with the Cancer Letter

    Storniolo: The Komen Tissue Bank fills the gap in understanding of “normal”

    Ten years ago, the formation of the Komen Tissue Bank at the Indiana University Melvin and Bren Simon Cancer Center was met with skepticism.

    Critics questioned the ethics of collecting “normal” breast tissue from healthy women who otherwise would have no other reason to undergo biopsies.

    Anna Maria Storniolo, a founder of the tissue bank and now its director, was one of those skeptics—before she started work on the bank in 2005.

  • ACS: Access and socioeconomic factors affect racial disparities in breast cancer mortality rates

    The disparity in survival outcomes between black and white women with breast cancer—the result of a complex interaction of biologic and nonbiologic factors—can be reduced by increasing access to health care in all U.S. states, researchers from the American Cancer Society concluded in a recent study.

  • Dmitrovsky named president of Leidos Biomedical and director of Frederick Lab

    Ethan Dmitrovsky was appointed president Leidos Biomedical Research, Inc. and Laboratory director of the Frederick National Laboratory for Cancer Research.

    Dmitrovsky will succeed the current president, David Heimbrook, who will retire.

    FNLCR is operated by Leidos Biomedical under an operations and technical support contract from NCI worth up to $400 million-a-year.

  • Help Wanted: MD Anderson seeks chief academic officer; Draetta named to the job in the interim

    MD Anderson has begun a search for a chief academic officer.

    Giulio Draetta will serve as CAO ad interim. Draetta is the Sewell Family Chair of Genomic Medicine, senior vice president, discovery and platforms and co-leader of the MD Anderson Moon Shots Program. Until now, Stephen Hahn, deputy president and chief operating officer, also served as interim chief academic officer.

  • In Brief

    • Pat Coyne and Meg Gaines receive NCCS Stovall Award for advancing patient-centered care
    • SU2C launches four teams on “cancer interception” to detect and treat cancer
    • SU2C launches 10 clinical trial projects combining cancer treatments
    • Barbara McAneny receives ACCC award
    • NCCN has one million registered users accessing the guidelines and related content
    • Fox Chase Cancer Center Opens Satellite Office in East Norriton
    • Xiongbin Lu named Vera Bradley Foundation professor of breast cancer innovation at IU
    • The GW Cancer Center announces new mobile mammography van
  • Drugs and Targets

    • FDA accepts Genentech’s application for Avastin for advanced ovarian cancer
    • G100 receives Orphan Drug Designation from EMA for follicular non-Hodgkin’s lymphoma

Copyright (c) 2017 The Cancer Letter Inc.